Singapore, June 25 -- Gilead Sciences, Inc., on 24 June 2019, announced that the Singapore Health Sciences Authority (HAS) has approved Vosevi (Sofosbuvir 400mg/Velpatasvir 100mg/Voxilaprevir 100mg), a once-daily single tablet regimen for the re-treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Vosevi is approved as a 12-week treatment regimen for patients with any genotype of chronic HCV infection, without cirrhosis, or patients with genotypes 1, 3 and 4 and compensated cirrhosis, who have previously failed therapy with a direct-acting antiviral (DAA) regimen containing NS5A inhibitor. A 12-week regimen is also approved for use in genotype 1-4 patients, without cirrhosis or with compensated cirrhosis, who ...